Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35969 PTC Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 04-3416587 (Stat ...

PTC Therapeutics (PTCT) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics First Quarter twenty twenty five Earnings Conference Call. All participants are in a listen only mode. After the presentation, there will be a question and answer session. Today's conference is being recorded. I would now like to turn the conference over to Ellen Cavallari, Head of Investor Relations. Please go ahead. Speaker1 Good afternoon and thank y ...

Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results – Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J., May 6, 2025 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update ...

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements with respect to the future expectations, plans and prospects for PTC, PTC's strategy, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters, ...

- Label includes full spectrum of PKU patients - - European launch preparations underway - WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the marketing authorization application for Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The opinion includes a broad label inclusi ...

Core Viewpoint - The European Commission has decided not to renew the authorization of Translarna™ (ataluren) for treating nonsense mutation Duchenne muscular dystrophy, although individual EU member states may still allow its use under specific provisions [1][2]. Company Overview - PTC Therapeutics, Inc. is a global biopharmaceutical company focused on developing and commercializing medicines for rare disorders, leveraging scientific expertise and a global commercial infrastructure to maximize value for patients [5]. Product Information - Translarna (ataluren) is a protein restoration therapy aimed at enabling the formation of functional proteins in patients with genetic disorders caused by nonsense mutations, specifically targeting Duchenne muscular dystrophy [3]. - Translarna is licensed in multiple countries for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged 2 years and older, while it remains an investigational new drug in the United States [3]. Disease Context - Duchenne muscular dystrophy is a rare and fatal genetic disorder primarily affecting males, leading to progressive muscle weakness and premature death due to heart and respiratory failure, with the absence of functional dystrophin protein being a critical factor [4].

— Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe intake with a mean increase of 126% — — Genetic variant analysis of Phase 3 APHENITY trial demonstrates meaningful effect in classical subjects with non-BH4 responsive genotypes — WARREN, N.J., March 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American Colle ...

PTC Therapeutics (PTCT) Q4 2024 Earnings Call February 28, 2025 03:30 AM ET Company Participants Ellen Cavaleri - Head of Investor RealtionsMatthew Klein - President & CEOEric Pauwels - Chief Business OfficerPierre Gravier - Chief Financial OfficerKelly Shi - Senior Vice PresidentTiago Fauth - Director - Equity Research Small/Mid Cap BiotechnologyEllie Merle - Executive DirectorGena Wang - MD - Biotech Equity ResearchPeyton Bohnsack - Biotechnology Equity Research - Vice PresidentTazeen Ahmad - MD - US Equi ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head of IR Matthew Klein - CEO Eric Pauwels - Chief Business Officer Pierre Gravier - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Tiago Fauth - Wells Fargo Eli Merle - UBS Gena Wang - Barclays Joel Beatty - Baird Sami Corwin - William Blair Peyton Bohnsack - TD Cowen Tazeen Ahmad - Bank of America Securit ...

For the quarter ended December 2024, PTC Therapeutics (PTCT) reported revenue of $213.17 million, down 30.6% over the same period last year. EPS came in at -$0.24, compared to -$0.24 in the year-ago quarter.The reported revenue represents a surprise of -3.96% over the Zacks Consensus Estimate of $221.96 million. With the consensus EPS estimate being -$0.96, the EPS surprise was +75.00%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...